Resources
Big Molecule Watch
- STADA and Alvotech Announce Launch of UZPROVO® in Europe July 26, 2024 Tara Thigpen
- FDA Issues Draft Guidance on Demonstrating Biosimilar Interchangeability July 25, 2024 Yoko Bian
- FDA Approves Samsung’s Eculizumab Biosimilar July 25, 2024 Emma Murray
- FTC Issues Interim Report on Ongoing Study of Pharmacy Benefit Managers July 23, 2024 Stephanie Dusaban Gonzales
- Outlook Therapeutics Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) July 12, 2024 Lihui Bai
- Fresenius Announces Launch of Subcutaneous Formulation of TYENNE (tocilizumab-aazg) in the United States July 9, 2024 Gabriella Montes
- FDA Approves Ustekinumab, Aflibercept, and Filgrastim Biosimilars July 9, 2024 Zachariah Holmes
- Biogen’s TOFIDENCE (tocilizumab) Approved in the EU June 28, 2024 Alison Siedor
- Eculizumab BPCIA Litigation Update: Court Denies Alexion’s Motion for an Injunction Pending Appeal June 26, 2024 Sam Herron
- Now Available! Announcing the Vaccine Patent Litigation and Vaccine Patent PTAB Trackers June 25, 2024 Ariana Harris
BioPharma Reporter
- AI revolution in pharma: Qinecsa's James Bellamy unveils groundbreaking PV tech insights July 26, 2024
- Funding boost to scale production for human vaccines and expand R&D labs July 26, 2024
- Third Arc Bio raises $165M series A to develop biologics for cancer and immunology July 25, 2024
- Biologics driving M&A as Agilent snaps up specialist BIOVECTRA for $925 million July 25, 2024
- Suzanne LeBlang - passionate about patient care and the Focused Ultrasound Foundation July 25, 2024
- Alvotech and Stada debut uzpruvo, the first ustekinumab biosimilar in Europe July 24, 2024
- Ensuring pharma data integrity: COPA-DATA’s automation solution tackles ALCOA challenges July 24, 2024
- Global biosimilar market estimated to reach a size of $43.8 billion by the end of 2024 July 24, 2024
- FDA approves Samsung Bioepis’ Epsyqli biosimilar for PNH and aHUS treatment July 24, 2024
- Boehringer Ingelheim and GoodRx undercut Humira by massive 92% with biosimilar July 24, 2024